Amachiza e-Paclitaxel athathwa njengonyango lokuqala lomhlaza wamabele, kwaye asetyenziswa ngokubanzi ekliniki kumhlaza wesibeleko, umhlaza wemiphunga, amathumba entloko kunye nentamo, umhlaza wombhobho, umhlaza wesisu kunye ne-sarcoma yezicubu ezithambileyo.Kwiminyaka yakutshanje, ngokuphononongwa okuqhubekayo kwamachiza e-paclitaxel kunye nokuphuculwa okuqhubekayo kwenkqubo yokuqulunqwa, la mayeza ngoku abandakanya inaliti ye-paclitaxel, i-docetaxel (i-docetaxel), i-liposomal paclitaxel kunye ne-albumin-bound paclitaxel.Ke yintoni umahluko phakathi kwala mayeza e-paclitaxel, masifunde ngakumbi ngawo apha ngezantsi.
I. Umahluko kwimisebenzi esisiseko
1. Inaliti ye-Paclitaxel: Iboniswa kumgca wokuqala kunye nonyango olulandelelweyo lomhlaza we-ovarian oqhubekayo, unyango lwe-adjuvant yomhlaza webele we-lymph node-positive emva kwerejimeni eqhelekileyo ye-adriamycin equlethe i-chemotherapy edibeneyo, umhlaza webele kumhlaza webele we-metastatic. iye yasilela indibaniselwano yechemotherapy okanye iphinde yabuyela emva kwiinyanga ezi-6 ze-adjuvant chemotherapy, unyango lokuqala lomhlaza wemiphunga weseli ongeyonxalenye encinci, kunye nonyango lodidi lwesibini lwe-AIDS ehambelana nesigulana se-carcinosarcoma.
2. I-Docetaxel: Kunyango lomhlaza webele ophezulu okanye we-metastatic oye wasilela ngaphambi kwechemotherapy;kunyango lomhlaza wemiphunga ophezulu okanye we-metastatic ongewona omncinci weseli oye wasilela nge-cisplatin-based chemotherapy.Ikwasebenza kumhlaza wesisu kunye nomhlaza wedlala lesinyi.
3. I-Liposomal paclitaxel: Inokusetyenziswa njenge-chemotherapy yomgca wokuqala womhlaza we-ovarian kunye ne-chemotherapy yokuqala yonyango lomhlaza we-ovarian metastatic, kwaye inokusetyenziswa ngokudibanisa ne-cisplatin.Isenokusetyenziswa kunyango olulandelelweyo lwezigulane zomhlaza wamabele eziye zanyangwa ngechemotherapy eqhelekileyo equlethe i-adriamycin okanye kunyango lwezigulana ezinokuphinda ziphinde.Isenokusetyenziswa ngokudityaniswa ne-cisplatin njengonyango lwechemotherapy yomgca wokuqala kwizigulana ezinomhlaza wemiphunga ongengowomncinci ongenako ukunyangwa ngotyando okanye ngeradiotherapy.
4. I-Albumin-bound paclitaxel: iboniswe kunyango lomhlaza webele we-metastatic oye wahluleka ukudibanisa i-chemotherapy okanye umhlaza webele oye waphinda wavela kwiinyanga ze-6 emva kwe-adjuvant chemotherapy.Ngaphandle kokuba kukho ukuchasana kweklinikhi, i-chemotherapy yangaphambili kufuneka ibandakanye i-anthracycline ye-anticancer agent.
II.Umahluko kukhuseleko lweziyobisi
1. I-Paclitaxel: ukunganyibiliki kakuhle kwamanzi.Ngokubanzi, inaliti iyakongeza i-polyoxyethylene-substituted oyile ye-castor kunye ne-ethanol ukuphucula ukunyibilika kwe-paclitaxel emanzini, kodwa i-histamine ikhutshwa xa i-polyoxyethylene-substitute oyile ye-castor ithotywa kwi-vivo, enokukhokelela ekuphenduleni okunzulu kwaye inokwenza mandundu. I-peripheral neurotoxicity ye-paclitaxel, kwaye inokuchaphazela ukusasazwa kweemolekyuli zamachiza kwizicubu kwaye ichaphazele isiphumo sokuchasana nethumba.
2. I-Docetaxel: i-solubility yamanzi iphantsi, kwaye kufuneka ihlanjululwe ngokudibanisa i-polysorbate 80 kunye ne-ethanol e-anhydrous, zombini ezo zinokunyusa ukuvela kweempendulo ezimbi kwaye zingabangela ukusabela kwe-allergic kunye ne-hemolytic.
3. I-Liposomal paclitaxel: ichiza lifakwe kwi-lipid-like bilayers ukwenza i-vesicles encinci, kwaye ichiza lifakwe kwi-liposomal particles ngaphandle kwe-polyoxyethylene-substituted oil castor kunye ne-anhydrous ethanol, ebangela ukusabela kwe-allergic.Nangona kunjalo, uphando lubonise ukuba ichiza le-paclitaxel ngokwalo linokubangela ukusabela kwe-hypersensitivity, kodwa ngesantya esisezantsi xa kuthelekiswa nenaliti ye-paclitaxel.Okwangoku, i-paclitaxel liposomes isafuna unyango lwangaphambi kokwaliwa ngaphambi kokusetyenziswa.
4. I-Albumin-bound paclitaxel: I-albumin entsha ye-albumin lyophilized agent esebenzisa i-albumin yomntu njengomphathi weziyobisi kunye ne-stabilizer, engaqulathanga i-co-solvent polyoxyethylene-substituted oyile ye-castor kwaye inomxholo ophantsi wepaclitaxel kunye ne-paclitaxel liposomes, kwaye ayinayo. funa unyango lwangaphambili phambi kokuba unyango.
Qaphela: Ukusebenza okunokubakho kunye nokusetyenziswa okugutyungelwe kule ntetho kuthatyathwe kuncwadi olupapashiweyo.
I-Yunnan Hande Biotechnology Co., Ltd ibisebenza ngokukhethekileyo kwimveliso yepaclitaxel APIngaphezu kweminyaka engama-20, kwaye yenye yabakhiqizi abazimeleyo behlabathi be-paclitaxel API, ichiza eliphuma kwisityalo elichasene nomhlaza, elivunywe yi-US FDA, i-European EDQM, i-Australian TGA, i-CFDA yaseTshayina, i-India, iJapan kunye nezinye ii-arhente ezilawulayo zelizwe. .I-Hande inokubonelela kuphela ngomgangatho ophezulupaclitaxel imathiriyeli ekrwada, kodwa kunye neenkonzo zophuculo lobugcisa ezinxulumene nokuqulunqwa kwe-paclitaxel.Ngolwazi oluthe vetshe, nceda ukhululeke ukunxibelelana nathi apha 18187887160.
Ixesha lokuposa: Dec-08-2022